Clinical trials
Diffuse Intrinsic Pontine Glioma clinical trials
Below are recruiting diffuse intrinsic pontine glioma clinical trials, each written for real people, not researchers. We’re tracking 36 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06333899RecruitingEarly Phase 1
Lorlatinib for newly diagnosed brain tumors with ROS or ALK fusion
This trial tests if lorlatinib, a targeted pill, can shrink or slow the growth of high-grade brain tumors that have a specific ROS or ALK genetic change. It is for children and young adults who have not yet had treatment for their tumor.
Aurora, ColoradoAges 1–21 - NCT06624371RecruitingPhase 1
Atovaquone with radiation for children with brain tumors
This trial tests adding atovaquone to standard radiation therapy for children with aggressive brain tumors like high-grade glioma (a fast-growing brain cancer) or medulloblastoma. The goal is to see if this drug, which targets energy production in cancer cells, can make radiation work better.
Atlanta, GeorgiaAges 2–25 - NCT06838676RecruitingPhase 2
ACT001 for DIPG and H3K27-altered high-grade gliomas
This trial tests a drug called ACT001 for people with diffuse intrinsic pontine glioma (DIPG) or certain high-grade gliomas that have a specific genetic change (H3K27-altered). It includes two groups: one for newly diagnosed DIPG after radiation, and another for progressive or recurrent disease.
Aurora, ColoradoAges 1–39 - NCT04837547RecruitingPhase 1
Personalized cell therapy for childhood cancer
This trial tests a new, personalized cell therapy for children with high-risk neuroblastoma or DIPG (a type of brain tumor) that has come back or is hard to treat. It uses the patient's own tumor to create a treatment that might work better for them.
Gainesville, FloridaAges 1–30 - NCT01106794Recruiting
Test of tumor sample analysis for brainstem glioma
This trial analyzes tumor tissue or samples to learn more about brainstem gliomas, including a common type called diffuse intrinsic pontine glioma. The results may help doctors better understand these tumors and guide future treatments.
Washington D.C., District of ColumbiaAges Up to 21 years - NCT07501156RecruitingPhase 1/Phase 2
Immune Cell Therapy for H3K27M-Positive Brain Tumors
This trial tests a personalized immune cell therapy for people with a specific type of brain tumor (DIPG or midline glioma) that has the H3K27M mutation. The treatment uses your own immune cells, which are modified to find and attack the tumor.
Shenzhen, GuangdongAges 2–70 - NCT07584499RecruitingPhase 1
New drug test for children with EGFR-positive solid tumors
This study tests a new cancer drug called Becotatug Vedotin in children ages 2–18 with certain types of solid tumors (cancers that form in organs or tissues) that have an EGFR protein. The drug is designed to find tumors with this protein and attack cancer cells while sparing healthy ones.
Guangzhou, GuangdongAges 2–18 - NCT07589257RecruitingPhase 2
VRT106 drug combined with radiation for brain stem tumors
This trial tests whether a new drug called VRT106, given alongside radiation therapy, can help treat a serious type of brain tumor called diffuse midline glioma or DIPG. The drug is designed to work with radiation to fight the cancer.
Guangzhou, GuangdongAges 18–75 - NCT03914768Enrolling by invitationPhase 1
Immune Cell Vaccine for Brain Tumors
This trial tests a vaccine made from immune cells (dendritic cells) designed to train your body to fight brain tumors like DIPG or glioblastoma. You may qualify if you have one of these tumors, have had standard treatment, and are generally healthy enough for the study.
Shenzhen, GuangdongAges 1–75 - NCT05553041RecruitingEarly Phase 1
PET-MRI scan test for aggressive brain tumors in children
This early-phase study uses a special PET scan plus MRI to help doctors tell apart tumor changes in children with aggressive gliomas. It may help find whether treatment is working or if the tumor is progressing, while also mapping tumor activity in the brain.
Philadelphia, PennsylvaniaAges 1–21 - NCT06896110Enrolling by invitationPhase 1
Spinal chemo and immunotherapy for recurrent high-grade glioma
This trial tests a combination of two drugs—azacitidine and nivolumab—given directly into the spinal fluid for people whose high-grade glioma has come back after initial treatment. The goal is to see if this approach can safely target the tumor and slow its growth.
Iowa City, IowaAges 13 years+ - NCT05580562RecruitingPhase 3
ONC201 for newly diagnosed H3 K27M brain tumor after radiation
This study tests whether ONC201 (also called ONC201) can improve outcomes for people with a newly diagnosed H3 K27M–mutant diffuse brain tumor after they finish radiation. It looks for safety and whether treatment can help control the tumor.
Phoenix, ArizonaAges Any age
Hear when a new Diffuse Intrinsic Pontine Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for diffuse intrinsic pontine glioma?
- Yes. Clin2 currently lists 36 recruiting diffuse intrinsic pontine glioma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a diffuse intrinsic pontine glioma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a diffuse intrinsic pontine glioma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.